Dergiler / The anatolian journal of family medicine (Online) / 2019 / Cilt: 2 - Sayı: 1

Prevalence of Non-Alcoholic Fatty Liver Disease in Patients with Parkinson Disease

Sayfa
38–40
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In multiple logistic regression analyses using baseline factors, statin use, elevated HbA1c, baseline fasting glucose below than 100 mg/dL, and elevated ALT levels wereindependently associated with NAFLD (p=0.040, p<0.001, p=0.030, and p<0.001, respectively).Conclusion: While additional studies in large populations are needed to investigate the correlation betweenPD and NAFLD, further exploration of PD-related metabolic liver disease clinically appears warranted.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Non-alcoholic fatty liver disease (NAFLD) has presented as the most common cause of chronicliver disease in the Western world.
📊
Temel Bulgular & Veri:Our study aims to analyze the prevalence ofultrasonography-proven NAFLD among the PD patients.Methods: A retrospective chart review was performed to identify PD patients who had at least two visits inthe Liver Clinic from January 2017 to May 2018.
💡
Sonuç & Katkı:In multiple logistic regression analyses using baseline factors, statin use, elevated HbA1c, baseline fasting glucose below than 100 mg/dL, and elevated ALT levels wereindependently associated with NAFLD (p=0.040, p<0.001, p=0.030, and p<0.001, respectively).Conclusion: While additional studies in large populations are needed to investigate the correlation betweenPD and NAFLD, further exploration of PD-related metabolic liver disease clinically appears warranted.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2017 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: Non-alcoholic fatty liver disease (NAFLD) has presented as the most common cause of chronicliver disease in the Western world. Parkinson disease (PD) is these most common non-demyelinizan neurologic disase and its incidence is steadily increasing in the world. Our study aims to analyze the prevalence ofultrasonography-proven NAFLD among the PD patients.Methods: A retrospective chart review was performed to identify PD patients who had at least two visits inthe Liver Clinic from January 2017 to May 2018. Thus, 124 consecutive patients with PD was longitudinallyscreened for NAFLD which were diagnosed according to ultrasonographic criteria. Control subjects were selected from age-matched eldely subjects. Demographic and laboratory data, concurrent statin use and resultsof hepatobiliary ultrasonography were collected.Results: Non-alcoholic fatty liver disease prevalence was significantly lower in the PD group than in the agematched control group (21.0% vs. 36.9%, p=0.014). In multiple logistic regression analyses using baseline factors, statin use, elevated HbA1c, baseline fasting glucose below than 100 mg/dL, and elevated ALT levels wereindependently associated with NAFLD (p=0.040, p<0.001, p=0.030, and p<0.001, respectively).Conclusion: While additional studies in large populations are needed to investigate the correlation betweenPD and NAFLD, further exploration of PD-related metabolic liver disease clinically appears warranted.

🔖

Bu Makaleye Atıf Yap

VURAL, S., AYVAZ, M., KESİCİOĞLU, T., TURFAN, S., AYRALER, A., DÜLGER, A. C. (2019). Prevalence of Non-Alcoholic Fatty Liver Disease in Patients with Parkinson Disease. The anatolian journal of family medicine (Online), Cilt: 2 - Sayı: 1, 38–40. https://ajindex.com/articles/365074

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Dharmalingam M, Yamasandhi PG. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Indian J Endocrinol Metab 2018;22(3):421-8. [CrossRef] 2. Fernandez HH. 2015 Update on Parkinson disease. Cleve Clin J Med 2015;82(9):563-8. [CrossRef] 3. Bizzarri BM, Tortolini S, Rotelli L, Botta G, Saladino R.Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity. Curr Med Chem 2015;22(36):4138-65. [CrossRef] 4. Martín MG, Pfrieger F, Dotti CG. Cholesterol in brain disease: sometimes determinant and frequently implicated. EMBO Rep 2014;15(10):1036-52. [CrossRef] 5. Pierzchlińska A, Białecka M, Kurzawski M, Sławek J. The impact of Apolipoprotein E alleles on cognitive performance in patients with Parkinson's disease. NeurolNeurochir Pol 2018;52(4):477-82. [CrossRef] 6. Zhao H, Wang C, Zhao N, Li W, Yang Z, Liu X, et al. Potential biomarkers of Parkinson's disease revealed by plasma metabolic profiling. J Chromatogr B Analyt Technol Biomed Life Sci2018;1081-1082:101-8. [CrossRef] 7. Barros AS, Crispim RYG, Cavalcanti JU, Souza RB, Lemos JC, Cristino G, et al. Impact of the chronic omega-3 fatty acids supplementation in Hemiparkinsonism model induced by 6-Hydroxydopamine in rats. Basic ClinPharmacolToxicol2017;120:523–31. [CrossRef] 8. Rieu I, Boirie Y, Morio B, Derost P, Ulla M, Marques A, et al. The idiopathic Parkinson's disease: a metabolic disease? Rev Neurol (Paris)2010;166:822–8. [CrossRef] 9. Zhang J, Zhang X, Wang L, Yang C. High Performance Liquid Chromatography-Mass Spectrometry (LC-MS) Based Quantitative Lipidomics Study of Ganglioside-NANA-3 Plasma to Establish Its Association with Parkinson's Disease Patients. Med Sci Monit 2017; 23:5345-53. [CrossRef] 10. Bernhardt D, Müller HP, Ludolph AC, Dupuis L, Kassubek J. Body fat distribution in Parkinson's disease: An MRI-based body fat quantification study. Parkinsonism RelatDisord2016;33:84-9. 11. Doycheva I, Issa D, Watt KD, Lopez R, Rifai G, Alkhouri N. Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States. J Clin Gastroenterol 2018;52(4):339-46. [CrossRef]